This study was designed to compare the effect of low-molecular 6% hydroxyethyl starch (HES) 130/0.4 on hemostasis and hemodynamic efficacy with that of medium-molecular 6% HES 200/0.5 in patients undergoing off-pump coronary artery bypass surgery.
INTRODUCTION
Hydroxyethyl starch (HES) solutions are widely used for intravascular volume replacement. They are effective in volume therapy but they may cause coagulopathy when administered in large doses. High-molecular weight (MW) HES was reported to adversely affect on coagulation. 1, 2) On the other hand, many studies confirmed that newly developed low to medium MW, low-substituted HES such as 6% HES 130/0.4 (Voluven Ⓡ , Fresenius Kabi, Bad Homburg, Germany) and 6% HES 200/0.5 (HAES-steril Inj 6% Ⓡ , Fresenius Kabi, Bad Homburg, Germany) affect less on coagulation compared to that of high molecular HES solutions. [3] [4] [5] When these two HES solutions were compared during cardiac surgery under cardiopulmonary bypass, both colloids have demonstrated similar effect on coagulation and volume expansion. [6] [7] [8] [9] However, since cardiopulmonary bypass compromises coagulation system, the effect of a volume expander on coagulation profile would be better studied during off-pump coronary artery bypass surgery (OPCAB). This study was designed to compare the effect of low-molecular 6% HES 130/0.4 on hemostasis and hemodynamic efficacy with that of medium-molecular 6% HES 200/0.5 in patients undergoing OPCAB.
MATERIALS AND METHOS
After obtaining the approval of the Institutional Review Board, written informed consent for the study was obtained from all patients. Forty-eight patients undergoing elective OPCAB were randomly divided into either the HES 130/0.4 group or the S 15 HES 200/0.5 group using a computer-generated randomized table.
Patients and anesthesiologists were blinded to the treatment group and an independent researcher transferred the maximum amount of study solution (33 ml/kg/d) into a collection bag, which was marked with patient's name and identification number. Patients who had medical histories of valvular heart disease, myocardial infarction within the previous 3 months, congestive heart failure (left ventricular ejection fraction ＜ 
Packed red blood cell
339 ± 192 344 ± 295 Chest tube drainage (ml) 713 ± 263 530 ± 247* Urine output (ml) 2,500 ± 800 2,400 ± 900 for comparisons between the groups was also used. A P-value of less than 0.05 was considered as statistically significant.
RESULTS
Patient characteristics and data from the perioperative period are listed in Table 1 and they were comparable. Fluid balance is listed in Table 2 . There were no differences in total amounts Twelve patients from each group were hypovolemic after the S 18 induction of anesthesia and hemodynamic data before (T0) and after (T1) HES loading are listed in Table 3 The changes in hemodynamic variables and oxygenation profiles throughout the study period are listed in Table 4 . At sternal closure (T2), heart rate and PCWP significantly increased in both groups. At T2, the decrease in DO2 and the increase in oxygen extraction ratio were significant in both groups compared to baseline values. In the ICU (T3), the heart rate and cardiac index significantly increased in both groups compared to the baseline values.
Laboratory data are presented in Table 5 . There were no significant differences in the hematologic variables and coagulation profiles between the two groups. Fibrinogen and antithrombin-III were significantly decreased at T2 compared to the baseline values in both groups. The increase in PT and the decrease in Hct, platelet count were statistically significant at T2 and T3 compared to the baseline values in both groups.
Biochemical variables were within normal limits throughout the study period in both groups. There were no differences in TEG parameters within the group and between two groups except maximum amplitude in HES 200/0.5 group, which was significantly decreased at T2 compared to the baseline value (Fig. 1) .
DISCUSSION
The present study demonstrated that in patients undergoing OPCAB, HES 130/0.4 showed similar hemodynamic efficacy with 200/0.5. Biochemical data representing liver and kidney function remained within normal limit after the surgery in both groups. On the other hand, the amount of postoperative bleeding, which was measured as chest tube drainage, was less in High molecular weight HES with high degree of substitution and high C2 to C6 ratio is reported to impair hemostasis. 1, 2) Although several human studies confirmed that medium molecular weight HES (MW 200,000 to 250,000) with a lower degree of substitution does not have same negative effect on hemostasis, medium MW HES also compromises platelet contribution to hemostasis by reducing the availability of fibrinogen binding sites on activated platelets. [11] [12] [13] On the other hand, recent studies on the effect of HES specifications on hemostasis report that HES 130/0.4 has smallest effect compared to other HES specifications and similar with gelatin, which has minimal effect on coagulation. 3, 14, 15) In this study, TEG data in the HES 130/0.4 group were similar within the group except maximum amplitude (Fig. 1) . The decrease in maximum amplitude compared to the baseline value at sternal closure (T2) in the HES 200/0.5 group was statistically significant, which was consistent with previous study. 
